Awarded through the Defense Threat Reduction Agency\u2019s<\/a> Joint Science and Technology Office, the five-year program is now moving a promising solution toward Investigational New Drug submission with the US Food and Drug Administration.<\/p>\n The effort centers on producing reactivators that can neutralize man-made neurotoxins<\/a> by restoring acetylcholinesterase<\/a>, a critical enzyme that regulates neurotransmitters responsible for signals between neurons, glands, muscle cells, and the brain.<\/p>\n Once completed, these reactivators are expected to be available in a sealed vial and be distributed to the US Armed Forces and its allies, establishing a standardized field-ready medical capability to enhance care for troops exposed to chemical threats.<\/p>\n \u201cBattelle has a long history<\/a> of working with the [Department of Defense] to develop medical countermeasures that protect military personnel from chemical threats,\u201d said<\/a> Drew Cawthon<\/strong>, business line director at Battelle.<\/p>\n \u201cWe are proud to continue supporting this important mission and to continue to drive next-generation solutions to emerging threats with a strong partner like CMC Pharmaceuticals.\u201d<\/p>\n CMC Pharmaceuticals assists on the program by handling chemistry, manufacturing, and controls tasks, including laboratory development, testing, formulation, and regulatory oversight.<\/p>\n \u201cProviding drug development services to the [US Department of Defense] to protect our troops against the threat of nerve agents is truly an honor,\u201d said Mike Radomsky<\/strong>, president of CMC Pharmaceuticals.<\/p>\n \u201cThis program adds to our existing and growing portfolio of improved therapeutics and medical countermeasures for the US government.\u201d<\/p>\n![\"\"](\"https:\/\/www.fie.undef.edu.ar\/ceptm\/wp-content\/uploads\/2026\/10\/7493992-2048x1365-1.jpg\")